Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial.
Yuki Ishibashi, Yoshinobu Onuma, Takashi Muramatsu, Shimpei Nakatani, Javaid Iqbal, Hector M Garcia-Garcia, Antonio L Bartorelli, Robert Whitbourn, Alexander Abizaid, Patrick W Serruys, undefined ABSORB EXTEND Investigators
EuroIntervention | Published : 2014
AIMS: Bioresorbable scaffolds are increasingly used in patients with coronary artery disease undergoing percutaneous coronary interventions. ABSORB EXTEND is an ongoing study that will recruit 800 patients. This report evaluates acute and late scaffold failure in the first 450 patients enrolled in ABSORB EXTEND who have completed 12 months follow-up. METHODS AND RESULTS: Clinical event data from the first 450 patients enrolled in ABSORB EXTEND have demonstrated low rates of ischaemia-driven MACE (4.2%) and target vessel failure (4.7%) at 12 months. There have been seven cases of device failure in this study: three cases of scaffold dislodgement (0.67%) and four cases of subacute or late scaf..View full abstract